Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-028636
Filing Date
2018-11-08
Accepted
2018-11-08 17:09:17
Documents
53
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sgmo-10q_20180930.htm 10-Q 1795014
2 EX-31.1 sgmo-ex311_7.htm EX-31.1 15470
3 EX-31.2 sgmo-ex312_6.htm EX-31.2 15814
4 EX-32.1 sgmo-ex321_8.htm EX-32.1 7619
  Complete submission text file 0001564590-18-028636.txt   6829033

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT sgmo-20180930.xml EX-101.INS 1727627
6 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20180930.xsd EX-101.SCH 42966
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sgmo-20180930_cal.xml EX-101.CAL 39985
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sgmo-20180930_def.xml EX-101.DEF 170757
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20180930_lab.xml EX-101.LAB 287335
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20180930_pre.xml EX-101.PRE 242553
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30171 | Film No.: 181170540
SIC: 2836 Biological Products, (No Diagnostic Substances)